[go: up one dir, main page]

WO2003046011A1 - Conjugue ciblant une cellule presentatrice d'antigene, cellule presentatrice d'antigene mise en contact avec ce conjugue, leur utilisation en vaccin ou en medicament et procedes servant a les preparer - Google Patents

Conjugue ciblant une cellule presentatrice d'antigene, cellule presentatrice d'antigene mise en contact avec ce conjugue, leur utilisation en vaccin ou en medicament et procedes servant a les preparer Download PDF

Info

Publication number
WO2003046011A1
WO2003046011A1 PCT/EP2001/014255 EP0114255W WO03046011A1 WO 2003046011 A1 WO2003046011 A1 WO 2003046011A1 EP 0114255 W EP0114255 W EP 0114255W WO 03046011 A1 WO03046011 A1 WO 03046011A1
Authority
WO
WIPO (PCT)
Prior art keywords
conjugate
cells
antigen presenting
presenting cell
moiety
Prior art date
Application number
PCT/EP2001/014255
Other languages
English (en)
Inventor
Wilfred Germeraad
Original Assignee
Crucell Holland B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland B.V. filed Critical Crucell Holland B.V.
Priority to AU2002231655A priority Critical patent/AU2002231655A1/en
Priority to PCT/EP2001/014255 priority patent/WO2003046011A1/fr
Priority to US10/497,088 priority patent/US20060088520A1/en
Priority to EP02798320A priority patent/EP1451226A1/fr
Priority to PCT/EP2002/013681 priority patent/WO2003046012A1/fr
Priority to AU2002363861A priority patent/AU2002363861A1/en
Priority to NZ533226A priority patent/NZ533226A/en
Priority to CA002468878A priority patent/CA2468878A1/fr
Publication of WO2003046011A1 publication Critical patent/WO2003046011A1/fr
Priority to US10/856,272 priority patent/US20050037001A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • the present invention relates to a conjugate for targeting antigenic material to antigen presenting cells, pharmaceutical preparations containing conjugates or antigen presenting cells (APC) so produced, and to conjugates or APCs for use in medical treatment.
  • the invention further relates to the use of such conjugates to manufacture medicaments for the prophylactic and/or therapeutic, treatment of humans or animals to treat or prevent disease or discomfort.
  • Conjugates for targeting antigenic moieties to antigen presenting cells are known as such. They typically comprise at least one antigenic moiety conjugated to a targeting moiety.
  • the targeting moiety determines the type of antigen presenting cell that is targeted.
  • the antigenic moiety is the part of the conjugate which, after internalization, is processed by the machinery of the antigen presenting cell, and fragments thereof are presented via MHC class I or MHC class II molecules. This results in CTL activation and Th cell activation, respectively, thereby inducing an antigenic moiety specific immune response which is either of the humoral type or of the Cytotoxic T-cell type.
  • CTL activation is essential for killing tumor cells.
  • cytokines produced by Thl-cells are necessary.
  • Th2-cells are necessary for stimulating the B-cells.
  • Wallace et al, 2001 reported that targeting anti-Fc gamma Rl to a myeloid cell line using Fab-PSA (prostate specific antigen) resulted in a MHC class I associated presentation.
  • Fab-PSA prote specific antigen
  • a conjugate for targeting antigen presenting cells comprising: at least one antigenic moiety conjugated to a targeting moiety that is capable of binding to a cell surface structure of an antigen presenting cell, and upon binding inducing a CTL response and a T-helper resonse.
  • Nucleic acid sequence comprising a nucleic acid sequence encoding the antigenic moiety of claim 1 and a nucleic acid sequence encoding the targeting moiety of claim 1.
  • Method for producing a conjugate according to claim 1 comprising the steps of culturing host cells according to claim 19 under conditions allowing expression of the nucleic acid encoding the conjugate whereby the conjugate is formed, and isolating the conjugate from the cells and/or culture medium.
  • Method for generating an antigen presenting cell capable of eliciting an immune response via MHC class I and MHC class II presentation of processed antigen fragments comprising the step of contacting an antigen presenting cell with a conjugate according to claim 1-14.
  • Antigen presenting cell obtainable with the method of claim 21.
  • the present invention provides, by way of targeting a conjugate comprising an antigen determining moiety and a targeting moiety with specificity for antigen presenting cells, for the targeted delivery, up-take, processing and presentation of antigenic material by antigen presenting cells, whereby antigenic fragments oi said conjugate are presented via MHC class I and class II molecules causing by inducing a CTL response and a T-helper response an effective induction of all arms of the adaptive immune system.
  • the antigenic moiety is of parasitic, fungal, bacterial, viral or autologous (tumor) origin
  • the conjugate functions as an anti-parasitic, anti-fungal, antibacterial, anti-viral or anti-tumor agent, respectively.
  • the antiger presenting cell which presents antigenic moiety fragments may be generated in vitro or in vivo. This means that both the conjugate and antigen presenting cell contacted with the conjugate in vitro or in vivo is suitable for use in prophylactic or therapeutic vaccination and as a medicament for the antigenic moiety related diseases.
  • A- full immune response is obtained when an antigenic moiety is taken up, processed and presented by the professional antigen presenting cell.
  • Immunotherapy is an option for local tumors and metastasis after surgery.
  • Immunotherapy requires a humoral response and a cellular response.
  • a CTL activation class I restricted
  • Th cell activation class II restriction
  • T-helper responses lead to better CTL activity (Thl) as well as humoral responses (Th2).
  • the present invention is based on the finding that a conjugate comprising an antigenic moiety conjugated to a targeting moiety results after internalization and processing by the antigen presenting cell to a presentation of antigenic moiety fragments by both MHC class I and MHC class II molecules and in an antigenic moiety specific adaptive immune response.
  • the conjugate for targeting antigen presenting cells comprises at least one antigenic moiety conjugated to a targeting moiety.
  • the targeting moiety specifically directs the conjugate to a cell surface structure of the antigen presenting cell.
  • the antigen presenting cell may be a B-cell, a monocyte, or a dendritic cell. These cells may originate from blood, tonsil, synovial fluid or bone marrow. In blood the B-cells may be CD19 + cells, in tonsil CD19 + B-cells. The monocytes may be in blood CD14 + monocytes and in bone marrow CD14 + monocytes. The dendritic cells may be mature or precursor dendritic cells. Particular groups are CD33 + CD14- dendritic cells and CD33 dlm CDl 6 " dendritic cells. Many different types of dendritic cells exist within the organism, in particular at interfaces with the outside environment in order to pickup invaders.
  • the first population comprises of CD33 dim CD14 _ CD16 " cells (Thomas et al . , 1993; Thomas and Lipsky, 1994), by others called the CDllc " DC lacking lineage-specific markers (Lin-; O'Doherty et al . , 1994).
  • the Lin " HLA-DR + cells express high levels of CD123 (Olweus et al . , 1997).
  • DCs are thought to represent a precursor population capable of taking up and processing antigen but are less efficient to present the resulting peptides to T cells. They phenotypically resemble a DC precursor population that can be found in the paracortex of lymphoid tissues (Grouard et al . , 1997).
  • the second blood DC population is characterized by CD33 + CD14 ⁇ CD16 ⁇ , or can be identified as Lin " CDllc + . These latter cells are considered more mature as they can better present antigen than the precursor DC population (Thomas and Lipsky, 1994) . Similar cells can been found in germinal centers of follicles in lymphoid tissue (Grouard et al . , 1996) .
  • Antigen presenting cells have in principle the capability after binding of the conjugate to a particular cell surface structure of internalization and processing of the antigenic moiety of the conjugate and presentation of processed antigenic moiety fragments via both' MHC class I and MHC class II molecules. However, it is not known in detail what determines whether antigen fragments are presented via MHC class I or II, or both.
  • the targeting moiety is capable of binding to a cell surface structure of the antigen presenting cell via a specific immunological binding.
  • the targeting moiety may be selected from an immunoglobulin or a fragment thereof, such as a scFv fragment, Fab fragment, (Fab) 2 fragment.
  • Decisive is a specific binding of the targeting moiety to a cell surface structure of a particular antigen presenting cell.
  • the targeting moiety is of a monoclonal nature, which improves its selective binding to its target cell surface structure.
  • the targeting moiety is humanized or human in order to reduce its inherent antigenic properties.
  • the targeting moiety is in a multimeric form, in particular multimeric forms of immunoglobulin fragments.
  • the targeting moiety comprises an IgG4 subtype immunoglobulin.
  • a particular group of targeting moieties according to the invention is formed by monoclonal phage antibodies, such as MatDCll, MatDCl ⁇ , MatDC27, MatDC51 andMatDC64.
  • MatDCl ⁇ shows preferred targeting properties for mature and precursor dendritic cells, monocytes, such as CD14 + monocytes, CD19 + B-cells in blood, for a subpopulation of granulocytes, and CD19 "1" B-cells in tonsil, for mature and precursor dendritic cells and CD33 + CD14 + monocytes in synovial fluid and for CD14 + monocytes and CD15 + and CD34 + —cells in bone marrow.
  • MatDCl ⁇ has VH sequences shown in figure 1.
  • the CDR3 region of the VH region is ASLYSKFDY.
  • the VL chain is of the Vk2 subtype. Obviously, encountered are also affinity mature mutants thereof.
  • the conjugate comprises at least one antigenic moiety. It may be a peptide, polypeptide, protein, glycoprotein, lipoprotein, or a derivative or fragment thereof.
  • a derivative or fragment thereof means a part of processed version of the antigenic moiety in which is preserved the particular antigenic reactive part or epitope. It is noted that many antigenic moieties comprise more than one epitope.
  • This antigenic moiety may be of parasitic origin, such as plasmodium vivax merozoite surface protein 1, acidic basic repeat antigen of plasmodium falciparum, plasmodium falciparum liver stage antigen-3.
  • antigenic moieties from fungal origin are members of the aspartyl proteinase family, 65kDa mannoprotein antigen and' yeast-killer toxin receptor.
  • Antigenic moieties of bacterial origin may be exemplified as those relating to the diseases pneumonia, meningitis and bacteremia.
  • Examples of antigenic moieties from viral origin are env, gag, S major env, preS2 middle, G2Na.
  • Antigenic moieties of autologous origin, such as tumors are exemplified as MAGE, such as MAGE-1 (melanoma-associated antigen) , MAGE-3, gplOO, Muc-1, Her2/neu, PSA, PSMA and CEA.
  • MAGE-1 is a well- characterized tumor antigen already used in clinical trials (Rosenberg et al, 1998; Rosenberg et al, 1999; Nestle et al, 1999), was chosen for this study. In the past years, melanoma-specific CTL clones have served as tools to identify genes that code for tumor antigens (Boon et al, 1996) .
  • the MAGE gene family includes at least 17 related genes, namely MAGE-A1 to A12, MAGE-B1 to B4, and MAGE-Cl.
  • MAGE genes are expressed by tumors of various histological types, but they are silent in normal cells, with the exception of male germ-line cells that do not carry MHC class I molecules and are therefore unable to present antigens to CTL.
  • antigens encoded by MAGE-A, -B, -C genes should be strictly tumor specific. Because the MAGE antigens are shared by many tumors and on account of their strict tumor specificity, they are of particular interest for cancer immunotherapy.
  • Gene MAGE-A1 was isolated because it encoded an antigen presented on HLA-A1 molecules to autologous CTL of a melanoma patient (van der Bruggen et al .
  • a preferred targeting moiety is formed by MatDCl ⁇ , which is a monoclonal phage antibody binding to blood CD33 + CD14 " CD16 " mature dendritic cells. It is not required that the antigenic moiety of the conjugate is in the form of an amino acid sequence.
  • the antigenic moiety may be in the form of a nucleic acid sequence which encodes the antigenic peptide, polypeptide or protein, or a precursor thereof.
  • the antigenic moiety is preferably in the form of an expression vector.
  • nucleic acid sequences which may be used to express gene sequences in mammalian cells, such as human dendritic cells, are well known to those skilled in the art.
  • the antigenic moiety in the form of a nucleic acid sequence is conjugated to a targeting moiety which has the form of an immunoglobulin or fragment thereof.
  • the antigenic moiety is in the form of an expression vector, it is preferred for expression that the nucleic acid sequence encoding the antigenic moiety is operably linked with expression sequences for the antigen presenting cell for which the conjugate targets.
  • the expression sequence comprises a promoter obtainable from hCMV and/or a polyA signal obtainable from the bovine growth hormone.
  • the conjugate may be formed by conjugating a particular antigenic moiety to a particular targeting moiety. Conjugation may be obtained by any chemical conjugation mechanism. Conjugation could be between biotin-streptavidin complexes or via polymers such as poly-1-lysine (PLL) and polyethylenimine (PEI), could be Ni 2+ - ⁇ xHistidine tag binding, but not limited to these forms. It is preferred to produce the conjugate in a host cell which is transformed or transfected with a nucleic acid sequence encoding the antigenic moiety and the targeting moiety as a single polypeptide chain, although other forms of conjugation such as via S-S bridges are contemplated. The host cells are cultured in a culture medium under conditions allowing expression of the nucleic acid encoding the conjugate. The conjugate formed is isolated either from the cells or from the culture medium or from both. The host cells is preferred to be PerC ⁇ cells.
  • the contact of the conjugate and the antigen presenting cell may be carried out in vivo or in vitro.
  • In vitro a particular type of antigen presenting cells after its isolation and production is contacted in vitro with the conjugate in a contact medium. Due to the contact the antigen presenting cells after internalization and processing of the antigen moiety will be able to present at their surface via MHC class I and MHC class II molecules antigenic fragments of the antigenic moiety of the conjugate.
  • These antigen presenting cells are harvested from the medium and infused into the patient where presentation takes place of the processed peptides by the APC to CTL's and Thelper cells in vivo. These harvested antigen presenting cells may be used for prophylactic and/or therapeutic vaccination as a medicament or as an anti-parasitic, anti-fungal, anti-bacterial, anti-viral or anti-tumor agent. They may also be used in immunotherapy.
  • the contact of the conjugate with the antigen presenting cells may also be carried out in vivo.
  • the organism in which the antigen presenting cells occur is exposed to the conjugate via subcutaneous, intradermal, intramuscular or intravenous injection of the conjugate.
  • the targeting moiety of the conjugate directs the conjugate to the particular antigen presenting cells and after target binding the antigenic moiety of the conjugate is internalized, processed and subsequently fragments thereof presented via MHC class I and MHC class II molecules on the surface of the antigen presenting cell targeted.
  • those presenting antigen presenting cells in the organism function as a therapeutic agent for vaccination or medication for the above exemplified therapeutic uses .
  • the in vivo generation of antigen presenting cells eliciting immune responses via MHC class I and MHC class II presentation of the antigen fragments may also occur with a conjugate comprising the antigenic moiety in its nucleic acid encoding format.
  • the conjugate according to the invention and the antigen presenting cells eliciting via MHC class I and MHC class II presentation of processed antigen fragments of the conjugate demonstrate a new antigen (fragment) delivery and a more effective immune response, which makes these conjugates and conjugate activated antigen presenting cells optimal agents for vaccines and immunotherapies .
  • They are suitable for use in the treatment for in particular autologous and infectious diseases, such as Alzheimer, atherosclerosis, cancer, diabetes, AIDS, hepatitis.
  • This conjugate comprises as the antigenic moiety the MAGE-1 antigen.
  • This conjugate comprises as the antigenic moiety the MAGE-1 antigen.
  • monoclonal phage antibodies recognizing mature dendritic cells have been isolated.
  • the present invention is not restricted to this isolation procedure or specific antigen presenting cells.
  • the procedure may also be applied to in vitro monocyte derived dendritic cells, and any in vivo DC population from any particular organ as can be defined with specific antibodies (such as tonsil, skin, lung, liver, thymus) .
  • antigen presenting cells presenting fragments of MAGE-1 via MHC class I and MHC class II molecules on their surface and the biological activity, without considering the invention to be restricted thereto.
  • the library consists of a combination of 49 germline VH genes fused with ⁇ 10 8 synthetic heavy chain CDR3 regions and 7 light chains .
  • the CDR3 regions vary in length between 6 and 15 aminoacids .
  • the light chains are encoded by members of the V ⁇ l to V ⁇ 4 and V ⁇ l to V ⁇ 3 families .
  • the final library size consists of about 4xl0 8 individual clones .
  • PBMC peripheral blood mononuclear cells
  • AET 2-amino- ethylisothio-uroniyum bromide hydrobromide
  • the phage antibody library containing approximately 10 13 phage particles per ml, was blocked for 15 minutes in 250 ⁇ l of PBS/ 5% (w/v) milk powder. Subsequently, the obtained cell mixture consisting mainly of monocytes, B-lymphocytes and the described dendritic cells were added to the blocked phages and the mixture was slowly rotated overnight at 4°C.
  • the cells were washed twice with ice-cold PBS/1% (w/v) BSA and were stained with 20 ⁇ l PE-conjugated anti-CD33 antibody and 20 ⁇ l FITC-conjugated anti-CD14 antibody to visualize different cell populations on a flow cytometer. After 20 minutes incubation on ice, the cells were washed once with PBS/1% BSA and resuspended in 4 ml of PBS/1% BSA. Cell sorting was performed on a FACStar PLUS fluorescence activated cell sorter with the gates set around the CD33 + CD14 " mature DCs. For this cell population, 10 4 to 10 5 cells with phages still attached were sorted.
  • the cells were pelleted and transferred in a volume of 100 ⁇ l of M-PBS to a 15-ml tube containing 150 ⁇ l of sodium citrate (pH 2.5) . After 5 min, the pH was neutralized by adding 125 ⁇ l of 1 M Tris ⁇ Cl buffer (pH 7.4) . Finally, 3 ml of 2TY medium and 3 ml of log phase Escherichia coli XL-1 blue were added. Infection was allowed to proceed for 30 min. at 37 °C. Bacteria were centrifuged at 2,200 x g for 20 min, suspended in 0.5 ml of 2TY, and plated on agar.
  • the resulting PCR product was digested with BstNl for 1 hour at 37°C resulting in the appearance of various bands of different length.
  • BstNI fingerprint indicating differences in identity of individual phages
  • 5 MoPhabs named MatDCll, MatDCl ⁇ , MatDC27, MatDC51 and MatDC64 were propagated for further analysis.
  • VH and VL were determined using primer M13REV (5'- AACAGCTATGACCATG) and fdSeq (5' -GAATTTTCTGTATGAGG) in a sequence reaction with the Taq sequencing kit with the following cycling protocol: 96°C for 30 seconds denaturing, 50°C for 15 seconds annealing and 60°C for 4 minutes extension. Precipitated DNA was run and analyzed on a ABIPRISM automated fluorescent sequencer.
  • MatDC16 The binding of MatDC16 to subpopulations of PBMC was assessed by triple staining experiments with FITC-labeled CD14 and CDl 6, PECy5-labeled CD33 monoclonal antibodies and PE-labeled MoPhabs. For each experiment, 10 3 cells within the CD14 + CD16 " CD33 + monocyte gate, the CD14-CD16 " CD33 + mature DC and the CD14 ' CD16-CD33 dim precursor DC gates were analyzed. In addition, we performed double staining experiments with MatDCl ⁇ and fluorochrome-labeled lineage- specific monoclonal antibodies including CD3 (T lymphocytes) , CD19 (B lymphocytes) and CD56 (natural killer cells) .
  • MatDCl ⁇ Binding of MatDCl ⁇ to granulocytes was analyzed based on forward and side scatter profile. This MoPhab was obtained by phage selections on the CD14 + CD33 + monocyte population and recognizes the CD14 molecule, as determined by specific staining of CHO cells transfected with the human CD14 cDNA (results not shown) . As a negative control in staining experiments, a MoPhab specific for thyroglobuline (de Kruif et al . , 1995b) was used. MatDCl ⁇ brightly stained mature DC, but only a subpopulation of the precursor DCs. It also recognized the CD14 + CD16-CD33 + blood monocytes. No binding to blood CD3 + T cells or CD56 + NK cells was observed for MatDCl ⁇ , whereas it did bind to CD19' B cells.
  • Human tonsils contain DCs that can be identified as a CD3" CD4 + cell population that lacks lineage-specific markers. A further division of this population is obtained by staining with antibodies to CDwl23. Germinal center DCs, which consist of 65% of the CD3 " CD4 + DCs, are only weakly stained with this antibody (Grouard et al . , 1996), whereas the ⁇ remaining CD3 " CD4 + DC highly express this marker. Staining of tonsil cell with APC-labeled CD4, PE-labeled CDwl23 and FITC-labeled CD3 in combination with indirectly PerCP-labeled
  • MatDCl ⁇ was used to examine the reactivity with the different DC populations in tonsil ( Figure 7) .
  • MatDC16 stained the CDwl23 + DC, and the germinal center DCs. No T cells were recognized.
  • Triple- staining with antibodies specific for IgD and CD38 (Pascual et al . , 1994) and MatDCl ⁇ , revealed that MatDCl ⁇ stained the IgD + CD38 " naive B cells, the IgD " CD38 + germinal center B cells and the IgD " CD38 ++ plasma blasts. However, no staining of the IgD " CD38 " memory B cells was observed (results not shown) .
  • MatDCl ⁇ weakly stained CD34 + hematopoietic progenitor cells. It recognized the CD15 + CD14 " myeloid progenitor cells, but not the CD19 + B-lymphoid cells and CD3 + T lymphocytes . 7. REACTIVITY OF MATDC1 6 WITH SYNOVIAL FLUID MONONUCLEAR CELLS OF PATIENTS WITH RHEUMATOID ARTHRITIS
  • Synovial fluid (SF) from affected joints of patients with rheumatoid arthritis have been shown to contain increased numbers of DCs that may be involved in the prolongation and/or exacerbation of local immune-based inflammatory reactions (Thomas and Quinn, 1996; Hart, 1997) .
  • DCs and monocytes in SF may be identified based on the same characteristics as DCs in peripheral blood.
  • MatDCl ⁇ stained the mature DCs in SF, whereas a subpopulation of the precursor DCs was also positive.
  • Mean fluorescence intensity (MFI) levels for the different populations are shown as -, indicating the highest MFI in the first decade on a four log scale which corresponds to negative control levels.
  • the +, ++ and +++ indicate MFI in the second, third and fourth decades, respectively.
  • a slash (/) indicates that the MFI is on the border between two decades. Parenthesis indicate that less than 5% of the population is positive. *Approximately 50% of the population is positive for this MoPhab. #10-15% of the granulocytes are positive for this MoPhab.
  • CD34 + cells + -/+ • /+ 8 are CD34 + cells + -/+ • /+ 8 .
  • a fusion protein was constructed using the constant region of the heavy (H) chain of the human IgG4 gene and the entire coding region of the MAGE-1 molecule.
  • the IgG4 isotype was chosen for this approach since it has low affinity for Fc ⁇ RI and does not bind other Fc ⁇ receptors. In addition, it does not activate the complement system.
  • pHENMatDC16 was digested with Ncol and Xhol to obtain the VH region of MatDC16. Plasmid pLeader was digested with Ncol and Sail, into which sites the VH region was ligated.
  • Vector pCDNA3.1-C ⁇ 4 was made as follows. A Smal-Smal cDNA fragment encoding MAGE-1 was fused in-frame at the 3' terminus of the germline C ⁇ 4 gene, in which the stopcodon was removed, and cloned into pNUT-C ⁇ 4.
  • Vector pCDNA3.1-C ⁇ 4-MAGE-1 was made by cloning a BamHl-EcoRI fragment containing the C ⁇ 4-MAGE-1 cDNA into the same sites of pCDNA3.1+ . Sequence analysis on the whole gene cassette of 4 kb was performed and analysis indicated correctness. See Figure 2. Subsequently, any V H of interest, derived from a MoPhab or an antibody, or any antigen, be it tumor derived, viral, parasitic, bacterial or any other pathogenic organism can be cloned into this vector. VH cloning was performed for the constructs indicated in Table 2. 9. CONSTRUCTION OF A VECTOR FOR THE PRODUCTION OF A HUMAN IGG4-GP100 FUSION PROTEIN.
  • l-MatDC16-C ⁇ 4- MAGE-1 the Smal site 5' of the MAGE gene was changed into a Clal site by site directed mutagenesis.
  • the melanoma specific tumor antigen GP100 was PCR amplified with primers containing a Clal and a Smal site, respectively. This PCR fragment was cloned into pTOPO, sequenced and a correct clone was digested with Clal and Smal and ligated into Clal and Smal digested pCDNA3.
  • l-MatDC16-C ⁇ 4 producing plasmid pCDNA3.
  • Production and purification is similar as described below for pCDNA3.
  • the human immunodeficiency virus gene Gpl20 was PCR amplified with primers containing a Clal and a Smal site, respectively. This PCR fragment was cloned into pTOPO, sequenced and a correct clone was digested with Clal and Smal and ligated into Clal and Smal digested pCDNA3. l-MatDC16-C ⁇ 4, producing plasmid pCDNA3. l-MatDC16-C ⁇ 4-Gpl20.
  • Heterologous expression of protein is driven by the methanol inducible promoter for alcohol oxidase AOX1.
  • alcohol oxidase can contribute as much as 30% to the total protein produced, indicating the strength of AOX1 as a promoter.
  • the expression vector contains the ⁇ -vector mating sequence to facilitate protein secretion into the medium. At the point of secretion the signal sequence is cleaved from the expressed protein by the enzyme KEK2 ( Figure 3 and Figure 4) .
  • Ncol cloning site was introduced immediately after the cleavage point of the secretion-signal peptide (pPicZFVH) .
  • Vectors have been constructed to allow convenient insertion of fusion partners at the carboxyl tail of the scFv using the Notl and Xbal sites of the multiple cloning site in the vector (pPicZFVH-MAGE-Al, pPicZFVH-gplOO) .
  • a region from GplOO encompassing the immunodominant epitope has been amplified by PCR with primers containing the restriction sites Notl at the N-terminus and Xbal at the C-terminus.
  • the GP100 fragment was cloned into the vector pPicZFVH containing the scFv MATDC16 (pPicZFVH-MatDCl ⁇ -gplOO) .
  • the scFv MatDC16 can be easily exchanged with other scFv' s for analysis.
  • MAGE Al has been amplified by PCR with primers containing the restriction sites Notl at the N-terminus and Xbal at the C- terminus.
  • the MAGE gene was cloned into the vector pPicZFVH containing the scFv MATDC16. ( Figure 5) .
  • the antigen can be coupled to the antibody in the form of a
  • DNA plasmid encoding a viral or tumor-derived antigen.
  • the DNA plasmid needs to be condensed in order to get efficient uptake into the target cell. Therefore, we will make use of polymers such as poly-1-lysine (PLL) and polyethylenimine (PEI). Since coupling of a polymer to the N-terminus of a scFv potentially disrupts its binding capacity, we have prepared a modified pPicZFHV/MatDCl ⁇ construct. This modified construct encodes the MatDC16 scFv with an additional cysteine residue in front of the stopcodon, resulting in a C-terminal cysteine residue. This modified scFv will be produced as described before and used in subsequent coupling reactions.
  • a coupling reaction involves the following steps:
  • TN141, 3i-39, Monol4 and UBS54 are MoPhabs obtained in other experiments where other cells, DC or colon tumor cells were used as target cells for phage selections.
  • IgG4-MAGE-l fusion antibodies could serve as a source of antigen for immature DC, resulting in presentation via MHC class I and II.
  • MatDCl ⁇ -MAGE-1 that recognizes cultured immature monocyte-derived DC. This antibody also recognizes the immature Mo-DC. As negative controls, MatDC16 without MAGE-1 and UBS54-MAGE-1, that does not recognize immature DC, were used. In addition, IgG4 MONOl4-MAGE-1, a fusion antibody that binds to CD14 was included.
  • Immature monocyte-derived DC were cultured using IL-4 and GM-SCF following standard procedures from HLA.A1/DR1301 + donors. Immature DC were incubated with the fusion antibodies (10 nM or 100 nM) or control protein MAGE-Al (222nM) and cultured for 24 hrs or 4£ hrs. Subsequently, the DC were replated and cocultured with different T cell clones. Activation was assessed as IFN- ⁇ release in 24 hrs supernatants . Immature DC or CTL alone did not secrete detectable amounts of IFN- ⁇ ( ⁇ 80 pg/ml/24 h) .
  • the stimulatory capacity of the T cell clones was assured by exogenous peptide pulsing of the DC with either a MAGE-1.Al specific peptide, EADPTGHSY, in case of the CTL clone or a MAGE-1. DR13 specific peptide, LLKYRAEPVTKAE, in case of the T H clone (data not shown) .
  • a ' s can be seen in Figure 8, 100 nM IgGMatDC16-MAGE-l targeted to immature DC was enough to stimulate a response from the CTL, resulting in a significant amount of IFN- ⁇ production. No stimulatory activity can be seen for the negative control proteins MatDCl ⁇ , UBS54-MAGE-1 and MAGE-1.
  • IFN- ⁇ Upon addition of the MAGE-1 protein to immature DC, IFN- ⁇ was also produced by the T H clone. This is most likely the result of pinocytosis by the DC, ensuing in MHC class II presentation. Still, targeted delivery of MAGE-1 resulted in an almost two-fold up regulation of the IFN- ⁇ production by the T H clone, demonstrating the efficacy of this approach.
  • the effect seen with the IgG4 MON014-M1 may be caused by residual expression of CD14 on the immature DC or additional monocytes in the culture. Clear is that Mono-14 Ml targeting to Immature DCs only results in a TH activation and not in a CTL response. Taken together, these initial data demonstrate a very efficient induction of dual MAGE-Al responses, using MatDCl ⁇ IG4-MAGE-A1 fusion antibody targeted to DC.
  • FIGURES Figure 1 Amino acid sequence of VH region of MatDCl ⁇ Figure 2 Amino acid sequence of MatDCl6-C ⁇ 4-MAGE-Al Figure 3 Cloning site of pPicZcffi Figure 4 Cloning site of pPicZFVH Figure 5 pPicZFVH-Sl/23-hgplOO
  • FIG. 6 Northern blot analysis of transient Transfections : 1) mock; 2) IgG4 MatDC16; 3) IgG4 MatDCl 6-MAGE-1 ; 4) MAGE-1, probed with a MAGE-1 probe.
  • Figure 7 Western blot analysis of the purified IgG4 MatDC16-
  • Immature DC (10 5 ) derived from an HLA-A1+/HLA-DR1301+ donor were incubated with fusion Abs (lOnM or lOOnM) . Before adding the proteins, the DC were incubated with 20% human serum for 30 minutes on ice to block Fc ⁇ receptors. Either after (A) 24 or (B) 48 hrs of incubation, cocultures of DC (15000) with (I) CTL anti-MAGE-Al.Al or (II) T H anti-MAGE-Al .DR1301 (5000) were set up. Activation was assessed as IFN- ⁇ release at 24 hrs. Data are presented as picograms of IFN- ⁇ released/5xl0 3 /ml/24 hrs (mean ⁇ SD of triplicate cultures) .
  • Dendritic cells capable of stimulating T cells in germinal centres. Nature. 1996 Nov 28; 384 ( 6607) : 364-7.
  • Rosenberg SA A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 1999

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un conjugué servant à cibler un matériau antigénique vers des cellules présentatrices d'antigène, des préparations pharmaceutiques contenant des conjugués ou des cellules présentatrices d'antigène (APC), ainsi que des conjugués ou des cellules présentatrices d'antigène conçus pour être mis en application en traitement médical. Elle concerne, de plus, l'utilisation de ces conjugués afin de préparer des médicaments prophylactiques et/ou thérapeutiques pour l'homme ou l'animal, dans le but de traiter ou de prévenir des troubles ou des maladies.
PCT/EP2001/014255 2001-11-30 2001-11-30 Conjugue ciblant une cellule presentatrice d'antigene, cellule presentatrice d'antigene mise en contact avec ce conjugue, leur utilisation en vaccin ou en medicament et procedes servant a les preparer WO2003046011A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2002231655A AU2002231655A1 (en) 2001-11-30 2001-11-30 Antigen presenting cell targeting conjugate an antigen presenting cell contacted with such conjugate their use for vaccination or as medicament and methods for their production or generation
PCT/EP2001/014255 WO2003046011A1 (fr) 2001-11-30 2001-11-30 Conjugue ciblant une cellule presentatrice d'antigene, cellule presentatrice d'antigene mise en contact avec ce conjugue, leur utilisation en vaccin ou en medicament et procedes servant a les preparer
US10/497,088 US20060088520A1 (en) 2001-11-30 2002-11-29 Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
EP02798320A EP1451226A1 (fr) 2001-11-30 2002-11-29 Conjugue de ciblage de cellule de presentation de l'antigene, cellule de presentation de l'antigene mise en contact avec ledit conjugue, leur utilisation pour la vaccination ou en tant que medicament et leurs procedes de production ou de generation
PCT/EP2002/013681 WO2003046012A1 (fr) 2001-11-30 2002-11-29 Conjugue de ciblage de cellule de presentation de l'antigene, cellule de presentation de l'antigene mise en contact avec ledit conjugue, leur utilisation pour la vaccination ou en tant que medicament et leurs procedes de production ou de generation
AU2002363861A AU2002363861A1 (en) 2001-11-30 2002-11-29 Antigen presenting cell targeting conjugate, an intigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
NZ533226A NZ533226A (en) 2001-11-30 2002-11-29 Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
CA002468878A CA2468878A1 (fr) 2001-11-30 2002-11-29 Conjugue de ciblage de cellule de presentation de l'antigene, cellule de presentation de l'antigene mise en contact avec ledit conjugue, leur utilisation pour la vaccination ou entant que medicament et leurs procedes de production ou de generation
US10/856,272 US20050037001A1 (en) 2001-11-30 2004-05-28 APC targeting conjugate, an antigen-presenting cell contacted with such conjugate, their medical use, and methods of production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2001/014255 WO2003046011A1 (fr) 2001-11-30 2001-11-30 Conjugue ciblant une cellule presentatrice d'antigene, cellule presentatrice d'antigene mise en contact avec ce conjugue, leur utilisation en vaccin ou en medicament et procedes servant a les preparer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/856,272 Continuation-In-Part US20050037001A1 (en) 2001-11-30 2004-05-28 APC targeting conjugate, an antigen-presenting cell contacted with such conjugate, their medical use, and methods of production

Publications (1)

Publication Number Publication Date
WO2003046011A1 true WO2003046011A1 (fr) 2003-06-05

Family

ID=8164714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/014255 WO2003046011A1 (fr) 2001-11-30 2001-11-30 Conjugue ciblant une cellule presentatrice d'antigene, cellule presentatrice d'antigene mise en contact avec ce conjugue, leur utilisation en vaccin ou en medicament et procedes servant a les preparer

Country Status (2)

Country Link
AU (1) AU2002231655A1 (fr)
WO (1) WO2003046011A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0245078A2 (fr) * 1986-05-06 1987-11-11 Connaught Laboratories Limited Augmentation de l'immunogénicité d'antigènes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0245078A2 (fr) * 1986-05-06 1987-11-11 Connaught Laboratories Limited Augmentation de l'immunogénicité d'antigènes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BAIER G ET AL: "IMMUNOGENIC TARGETING OF RECOMBINANT PEPTIDE VACCINES TO HUMAN ANTIGEN-PRESENTING CELLS BY CHIMERIC ANTI-HLA-DR AND ANTI-SURFACE IMMUNOGLOBULIN D ANTIBODY FAB FRAGMENTS IN VITRO", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 69, no. 4, 1 April 1995 (1995-04-01), pages 2357 - 2365, XP002014861, ISSN: 0022-538X *
FANGER N A ET AL: "Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 APR 1997, vol. 158, no. 7, 1 April 1997 (1997-04-01), pages 3090 - 3098, XP001079509, ISSN: 0022-1767 *
LEKKERKERKER A ET AL: "Phage antibodies against human dendritic cell subpopulations obtained by flow cytometry-based selection on freshly isolated cells.", JOURNAL OF IMMUNOLOGICAL METHODS. NETHERLANDS 10 DEC 1999, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 53 - 63, XP004186074, ISSN: 0022-1759 *
SCHULTES B ET AL: "Antibody-antigen immune complexes allow for efficient MHC clas I and II-restricted antigen presentation and maturation of dendritic cells: a novel strategy for cancer immunotherapy", PROCEEDINGS OF THE 92ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. NEW ORLEANS, LA, MARCH 24 - 28, 2001, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA: ACCR, US, vol. VOL 42, 24 March 2001 (2001-03-24), pages 276, XP002202311 *
SCHULTES B ET AL: "Induction of CA125-specific B and T cell responses in MAb-B43.13 injected patients depends on complex formation of the MAb with circulating antigen in vivo", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 14, no. 6, 20 April 2000 (2000-04-20), pages A1003, XP002202309, ISSN: 0892-6638 *
SERRE K ET AL: "Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 DEC 1998, vol. 161, no. 11, 1 December 1998 (1998-12-01), pages 6059 - 6067, XP002209064, ISSN: 0022-1767 *
SHEN Z ET AL: "Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 MAR 1997, vol. 158, no. 6, 15 March 1997 (1997-03-15), pages 2723 - 2730, XP002094071, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
AU2002231655A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
US20060088520A1 (en) Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
US6682928B2 (en) Cells expressing anti-Fc receptor binding components
US10167328B2 (en) Methods for cancer therapy using mutant light molecules with increased affinity to receptors
JPWO2018225732A1 (ja) Ｍａｇｅ−ａ４由来ペプチドを認識する抗原結合性タンパク質
WO2001090198A1 (fr) Conjugues a composants multiples se liant a des molecules cibles et stimulant la lyse de cellules
WO2020155310A1 (fr) Nouvelle séquence d'acides aminés scfv, récepteur antigénique chimérique le comprenant et utilisation associée
JP2004500108A (ja) Ｎｋｇ２ｄレセプター複合体のエピトープへの結合部位を含む多機能ポリペプチド
JP2021522844A (ja) キメラ抗原受容体
KR20140130679A (ko) 이중 항원-유도된 이분 기능 상보성
US20070237771A1 (en) Multicomponent conjugates which bind to target molecules and stimulate T cell lysis
JP2023509765A (ja) 工学的修飾ｔ細胞、その調製および応用
US6440736B1 (en) Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules
KR20210143097A (ko) Cd22에 특이적인 항체 및 이의 용도
CN102120772B (zh) 一种嵌合抗体及免疫细胞
US20040068100A1 (en) Multicomponent conjugates which bind to target molecules and stimulate cell lysis
US20240156868A1 (en) Recombinant tim-4 protein, chimeric antigen receptor (car) t cell delivery system and methods of making and using same
WO2003046011A1 (fr) Conjugue ciblant une cellule presentatrice d'antigene, cellule presentatrice d'antigene mise en contact avec ce conjugue, leur utilisation en vaccin ou en medicament et procedes servant a les preparer
US20030161813A1 (en) Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules
EP4257608A1 (fr) Anticorps spécifique de cd47 et son utilisation
US20230212286A1 (en) Antibodies specific for cd22 and uses thereof
EP1001017A1 (fr) Modification des propriétés de cellules ou de particules pourvues de membranes dérivées de cellules par des molécules protéiniques modifiées par des lipides
WO2024119819A1 (fr) Marqueur polypeptidique et son utilisation
WO2024254775A1 (fr) Récepteur antigénique chimérique comprenant un nouveau domaine de costimulation et utilisation associée
JP2023509590A (ja) 工学的修飾ｔ細胞、その調製および応用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP